Difference between revisions of "Part:BBa K5302006"
Line 4: Line 4:
  
 
This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like.V114 has been identified as a small potent VEGF-binding peptide, which is composed of 8 amino acids--- that is VEPNc[CDIHVnLWEWEC]FERL, and there is a disulfide bond between N and F, making the stucture more stable. This peptide has a similiar structure and VEGF-binding site as V107, and it shows great affinity with VEGF(Kd=0.11 μM). We used pBBR1MCS-2 plasmid as a backbone and transfered V114 into Escherichia coli Nissle 1917, and finally succeeded in expressing V114.
 
This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like.V114 has been identified as a small potent VEGF-binding peptide, which is composed of 8 amino acids--- that is VEPNc[CDIHVnLWEWEC]FERL, and there is a disulfide bond between N and F, making the stucture more stable. This peptide has a similiar structure and VEGF-binding site as V107, and it shows great affinity with VEGF(Kd=0.11 μM). We used pBBR1MCS-2 plasmid as a backbone and transfered V114 into Escherichia coli Nissle 1917, and finally succeeded in expressing V114.
 +
 +
<html>
 +
<div style="text-align:center;">
 +
    <img src="https://static.igem.wiki/teams/5302/images/part-registry-v114-1.png"
 +
        width="60%" style="display:block; margin:auto;" alt="Jamboree Program" >
 +
    <div style="text-align:center;">
 +
        <caption>
 +
            <b>Figure 1. </b> This picture shows its VEGF-binding site and its affinity with VEGF
 +
        </caption>
 +
    </div>
 +
</div>
 +
</html>
  
 
<!-- Add more about the biology of this part here
 
<!-- Add more about the biology of this part here

Revision as of 07:52, 1 October 2024


V114

This year, the USTC iGEM team has utilized the competitive binding of vascular endothelial growth factor (VEGF) to develop a targeted bacterial therapy for solid tumors. Our quest for the optimal VEGF-binding protein(or peptide) led us to an in-depth exploration of proteins structurally akin to the vascular endothelial growth factor receptor (VEGFR), which we have named VEGFR-like.V114 has been identified as a small potent VEGF-binding peptide, which is composed of 8 amino acids--- that is VEPNc[CDIHVnLWEWEC]FERL, and there is a disulfide bond between N and F, making the stucture more stable. This peptide has a similiar structure and VEGF-binding site as V107, and it shows great affinity with VEGF(Kd=0.11 μM). We used pBBR1MCS-2 plasmid as a backbone and transfered V114 into Escherichia coli Nissle 1917, and finally succeeded in expressing V114.

Jamboree Program
Figure 1. This picture shows its VEGF-binding site and its affinity with VEGF

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]